Cyclomedica
ASX:CYCKingsgrove, Australia· Est.
Global leader in nuclear pulmonary imaging with Technegas® for diagnosis and management of respiratory diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Global leader in nuclear pulmonary imaging with Technegas® for diagnosis and management of respiratory diseases.
PulmonaryRespiratory
Technology Platform
Technegas® is a 99mTc‑labeled carbon aerosol inhaled by patients, providing high‑resolution ventilation imaging via SPECT/CT with low radiation dose and rapid acquisition.
Opportunities
U.S.
market entry post‑FDA approval and expanding indications into COPD, asthma and post‑COVID lung complications provide significant growth avenues.
Risk Factors
Reimbursement uncertainty, competition from alternative ventilation agents, and supply chain constraints for radiopharmaceutical production could affect market adoption.
Competitive Landscape
Key competitors include companies offering Xenon‑133 and Gallium‑68 ventilation agents; Technegas® differentiates through lower radiation dose, rapid imaging, and AI‑enhanced analysis.